跳转至内容
Merck
  • Par3L enhances colorectal cancer cell survival by inhibiting Lkb1/AMPK signaling pathway.

Par3L enhances colorectal cancer cell survival by inhibiting Lkb1/AMPK signaling pathway.

Biochemical and biophysical research communications (2016-12-03)
Taiyuan Li, Dongning Liu, Xiong Lei, Qunguang Jiang
摘要

Partitioning defective 3-like protein (Par3L) is a recently identified cell polarity protein that plays an important role in mammary stem cell maintenance. Previously, we showed that high expression of Par3L is associated with poor survival in malignant colorectal cancer (CRC), but the underlying mechanism remained unknown. To this end, we established a Par3L knockout colorectal cancer cell line using the CRISPR/Cas system. Interestingly, reduced proliferation, enhanced cell death and caspase-3 activation were observed in Par3L knockout (KO) cells as compared with wildtype (WT) cells. Consistent with previous studies, we showed that Par3L interacts with a tumor suppressor protein liver kinase B1 (Lkb1). Moreover, Par3L depletion resulted in abnormal activation of Lkb1/AMPK signaling cascade. Knockdown of Lkb1 in these cells could significantly reduce AMPK activity and partially rescue cell death caused by Par3L knockdown. Furthermore, we showed that Par3L KO cells were more sensitive to chemotherapies and irradiation. Together, these results suggest that Par3L is essential for colorectal cancer cell survival by inhibiting Lkb1/AMPK signaling pathway, and is a putative therapeutic target for CRC.

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human STK11